BLOOD PRODUCTS ADVISORY COMMITTEE 72nd Meeting - March 14-15, 2001 Gaithersburg Holiday Inn 2 Montgomery Village Avenue Gaithersburg, MD 20877

Thursday, March 14, 2002

8:00 a.m. Welcome, Statement of Conflict of Interest, Announcements

8:10 a.m. Committee Updates

- Nucleic Acid Testing for Whole Blood, Including Standards for HIV-1 and HCV RNA Indira Hewlett, Ph.D.
- Nucleic Acid Testing for Parvovirus B19 Mei-ying Yu, Ph.D.
- Nucleic Acid Testing for Hepatitis A Virus Gerardo Kaplan, Ph.D.
- Draft "Guidance for Industry on Precautionary Measures to Reduce the Possible Risk of Transmission of Zoonoses by Blood and Blood P roducts from Xenotransplantation Product Recipients and Their Intimate Contacts" - Andrew Dayton, M.D., Ph.D.
- Announcement of Planned FDA Workshops
 - 9:45 a.m. BREAK
- 10:00 a.m. Open Committee Discussion
 - I. Emergency Preparedness Informational Presentation
 - A. OBRR Strategic Plan Richard Lewis, Ph.D.
 - B. Supply Management AABB Task Force
 - C. Summary of PHS Advisory Committee on Blood Safety and Availability Meeting, January 31-February 1, 2002 - Stephen Nightingale, M.D.
 - D. OBRR Divisional Initiatives
 - •Division of Hematology Mark Weinstein, Ph.D.
 - •Division of Emerging and Transfusion Transmitted Diseases - Hira Nakhasi, Ph.D.
 - Division of Blood Applications Alan Williams, Ph.D.
- 12:30 p.m. OPEN PUBLIC HEARING
 - 1:00 p.m. Open Committee Discussion
 - E. Committee Discussion
 - 1:30 p.m. LUNCH

2:30 p.m. Open Committee Discussion

- II. Discussion on Percutaneous Exposure of Blood and Plasma Donors: Tattoos and Body Piercing
 - Introduction and Background Alan Williams, Α. Ph.D., Director, Division of Blood

Applications,

OBRR, FDA

Viral

в. Epidemiological Studies Evaluating Risk of Hepatitis Infection from Tattoos and Body Piercing - Miriam Alter, Ph.D., Chief, Epidemiology Branch, Division of Viral CDC

Hepatitis,

for Who

Blood

C. Prevalence and Characterization of Deferrals Tattoo, Accupuncture and Skin/Body Piercing Fail to Self-Defer - Sharyn Orton, Ph.D. Regulatory Project Manager, Division of Applications

- i) Donor Deferral Estimates
- ii) REDS Survey Data

3:30 p.m. BREAK

3:45 p.m. OPEN PUBLIC HEARING

Open Committee Discussion 4:45 p.m.

- Questions for the Committee Alan Williams, Ph.D.
- Committee Discussion and Recommendations
- RECESS (until 8:00 a.m., Friday, March 15, 2002) 5:30 p.m.

Friday, March 15, 2002

8:00 a.m. Open Committee Discussion

III. Review of Data Supporting Extension of Dating Period for Platelets

> A. Introduction and Background -Jaro Vostal, M.D., Ph.D., Chief, Laboratory Of Cellular Hematology, Division of Hematology OBRR, CBER B. Extension of Platelet Storage: Fact or Fantasy - Sherrill Slichter, M.D., Executive Vice President of Research, Puget Sound Blood Seattle, WA C. Safer, Cheaper and Just as Good: Making

> > Sterile, 7-Day Platelets a Reality - James

AuBuchon, M.D., Professor and Chair of Pathology, Dartmouth-Hitchcoock Medical Center, Lebanon, NH

- 9:30 a.m. OPEN PUBLIC HEARING
- 10:00 a.m. BREAK
- 10:30 a.m. Open Committee Discussion
 - D. Committee Discussion
- 11:30 a.m. LUNCH
- 12:30 p.m. Open Committee Discussion
 - IV. Bacterial and Fungal Contamination of Human Tissue Intended for Transplantation
 - A. Introduction and Background Ruth Solomon, M.D., Director, Human Tissue Staff, OBRR, CBER
 - B. Microbial Contamination and Cross
 Contamination Concerns During Processing of
 Tissue Mary Malarkey, Director, Division
 of Case Management, OCBQ, CBER, FDA
 - C. Preliminary Findings From an Investigation of Allograft-Associated Infections - Marion A.

Kainer, MBBS, MPH, FRACP, Epidemic Intelligence Service Officer, Division of Healthcare Quality Promotion, NCID, CDC D. Reducing the Risk of Tissue Transplant-

Transmitted Bacterial and Fungal Infections: Tissue Banks Perspective - D. Ted Eastlund, M.D., Head, Division of Transfusion

Medicine, Dept. of Lab Medicine, University of Minnesota Medical School

- E. Adverse Reactions (Endophthalmitis) AfterCorneal Transplantation: Eye BanksPerspective Michael A. Lemp, M.D., EBAA
- 2:30 p.m. OPEN PUBLIC HEARING
- 3:00 p.m. Open Committee Discussion
 - F. Committee Discussion
- 4:00 p.m. ADJOURNMENT